Novartis strikes a $1.9B partnership with Antares Therapeutics to tackle “undruggable” cancer targets.
Novartis has entered into a strategic collaboration and license agreement with Antares Therapeutics to discover and develop next-generation small molecule oncology treatments. The transaction...
Trodelvy Approved in Europe for Hard-to-Treat Breast Cancer Patients
The European Commission has granted marketing authorization for Trodelvy® (sacituzumabgovitecan) as an initial treatment for adults with unresectable or metastatic triple-negative breast cancer (mTNBC) who are ineligible...
Department of Pharmaceuticals urges Stakeholders to Submit Comments on Medical Device GTE Exemption List by July 15
The Department of Pharmaceuticals, under the Ministry of Chemicals and Fertilizers, has officially invited comments from stakeholders regarding proposed amendments to the Global Tender...
CDSCO Clarifies Approval Rules for Granules & Pellets, Bringing Regulatory Clarity to Pharma Industry
The Central Drugs Standard Control Organization (CDSCO), under the Directorate General of Health Services, has issued a comprehensive circular clarifying the regulatory and licensing...
Maiva Pharma launches brand-new, 22-acre sterile injectables plant in Tamil Nadu
Maiva Pharma Private Limited, a leading US FDA-approved sterile injectables manufacturer, has officially inaugurated its brand-new manufacturing plant. Spanning a sprawling 22-acre campus in Shoolagiri, Tamil Nadu, the...
EU approved Sanofi’s Cenrifki as first disability-taegeting medicine for SPMS
Sanofi announced that the European Commission has approved Cenrifki (tolebrutinib), marking a historic milestone as the first and only therapy authorized in the European Union specifically...
